A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
Status:
Completed
Trial end date:
2017-11-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of ixekizumab compared to fumaric
acid esters (FAE) and methotrexate (MTX) in participants with moderate-to-severe plaque
psoriasis who are naive to systemic treatment.